Aswan University Hospital

aswu.edu.eg

Total trials

95

Active

3

Phase 3

2

Total enrollment

16,284

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Botulinum toxin A1
Tadalafil 5mg1
full dose of Neostigmine1
half dose of Neostigmine1
Femoral nerve block with0.25% bupivacaine guided by ultrasound.1
PENG block with0.25% bupivacaine guided by ultrasound.1
Preoperative IV fentanyl 100microgram1

Next readouts

  • 2024-11-01
  • 2025-08-31
  • 2026-01

Top conditions

  • Cesarean Section Complications19
  • IUCD Complication8
  • Placenta Previa7
  • Infertility, Female5
  • Postoperative Pain4
  • Pre-Eclampsia3
  • Preeclampsia3
  • Acquired Deformity of Elbow2

Frequently asked questions about Aswan University Hospital

How many clinical trials does Aswan University Hospital have on ClinicalTrials.gov?
Aswan University Hospital is listed as the lead sponsor on 95 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
How many of Aswan University Hospital's trials are in Phase 3?
2 of Aswan University Hospital's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Aswan University Hospital focus on?
Aswan University Hospital's most-studied conditions on ClinicalTrials.gov are Cesarean Section Complications, IUCD Complication, Placenta Previa, Infertility, Female, Postoperative Pain.
When are Aswan University Hospital's next clinical trial readouts?
Aswan University Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl”, expected around 2024-11-01.